Trading update
H1 2025 revenues up 15% to £1.6m; losses £2.4m; cash £2.4m; FDA discussions progressing.
vs expectations: in line
- Revenue £1.6m (prior £1.4m)
- Gross profit margin 53% (prior 53%)
- Losses £2.4m (prior £2.4m)
- Cash £2.4m (prior £2.9m)
Select text to share a quote on X · sign in to keep highlights & notes in your GENI notes
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer announces a trading update for the 6 months ending 30 June 2025. The first half of 2025 saw continued strengthening of business, with revenues up 15% to £1.6m (30 June 2024 £1.4m) driven by growth across the UK, EU and US business. Gross profit margin remained firm at 53%, (30 June 2024 53%) with losses of £2.4m (30 June 2024 (£2.4m)). Cash at the end of June 2025 was £2.4m (30 June 2024 £2.9m). Trading remains broadly in line with the Board's overall expectations for the full year, with a busy second half period ahead.
FDA De Novo discussions continue to progress with work ongoing to close out the short list of remaining deficiencies. Collaboration discussions on potential US and EU test distribution are also advancing with a major distributer. New clinical data on CARDIO inCode-Score (polygenic risk score) was presented by Kaiser Permanente at the American Society of Preventive Cardiology (ASPC) in Boston in early August with a further presentation at this week's European Society of Cardiology (ESC) Annual Congress in Madrid (Aug 29th - Sept 1st) on the clinical importance of CARDIO inCode-Score in the modulation of cholesterol risk for coronary heart disease.
The Company will present its 2025 Interim Report at the end of September with the reporting date to be confirmed in due course.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.